A Retrospective Cohort Study of Upfront Nilotinib in Chronic Myeloid Leukemia: A Single-Center Experience

Context Nilotinib is a second-generation BCR-ABL1 tyrosine kinase inhibitor used in the treatment of chronic myeloid leukemia (CML). Aims We aim to evaluate the responses and safety of upfront Nilotinib therapy in Indian CML patients. Setting and Design We retrospectively revie...

Full description

Saved in:
Bibliographic Details
Main Authors: Reema Singh, Jyotsna Kapoor, Rayaz Ahmed, Pallavi Mehta, Vishvdeep Khushoo, Pragya Agrawal, Dinesh Bhurani, Narendra Agrawal
Format: article
Language:EN
Published: Thieme Medical and Scientific Publishers Pvt. Ltd. 2021
Subjects:
Online Access:https://doaj.org/article/f2f652b4c4ca41589504fa425f5e33b7
Tags: Add Tag
No Tags, Be the first to tag this record!